Share on StockTwits

Physicians Realty Trust (NYSE:DOC) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a report issued on Tuesday. They currently have a $13.70 price target on the stock. Zacks‘s price target points to a potential downside of 5.12% from the company’s current price.

Shares of Physicians Realty Trust (NYSE:DOC) traded up 0.35% on Tuesday, hitting $14.49. 77,412 shares of the company’s stock traded hands. Physicians Realty Trust has a 52-week low of $11.00 and a 52-week high of $14.77. The stock has a 50-day moving average of $14.34 and a 200-day moving average of $13.66. The company’s market cap is $491.9 million.

Physicians Realty Trust (NYSE:DOC) last announced its earnings results on Wednesday, August 13th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.06. The company had revenue of $11.40 million for the quarter, compared to the consensus estimate of $10.40 million. On average, analysts predict that Physicians Realty Trust will post $0.78 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on DOC. Analysts at Compass Point raised their price target on shares of Physicians Realty Trust from $16.00 to $16.50 in a research note on Thursday, August 14th. Separately, analysts at Oppenheimer raised their price target on shares of Physicians Realty Trust from $14.00 to $15.50 in a research note on Monday, August 11th. They now have an “outperform” rating on the stock. Finally, analysts at MLV & Co
initiated coverage on shares of Physicians Realty Trust in a research note on Friday, June 27th. They set a “buy” rating and a $16.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $15.21.

Physicians Realty Trust is a real estate investment trust (NYSE:DOC).

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.